News RA pill setback spoils Lilly’s growth story Eli Lilly has posted a strong 8% increase in sales for the second quarter, led by grow
News AbbVie looks beyond Humira as RA pill meets phase 3 targets Upadacitinib hopes drug will reduce reliance on Humira.
News FDA clears Viridian's Tepezza rival for thyroid eye disease Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
